Aquestive Therapeutics Inc (AQST)

$3.82 -0.04 (-1.04%)
Market Cap 470.93M
Revenue (ttm) 57.56M
Net Income (ttm) -44.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -76.69%
Debt to Equity Ratio -7.28
Volume 2,736,100
Avg Vol 5,387,356
Day's Range N/A - N/A
Shares Out 122.00M
Stochastic %K 61%
Beta 1.65
Analysts Strong Sell
Price Target $9.44

Company Profile

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 908 941 1900
Address:
30 Technology Drive, Warren, United States
drew64
drew64 Feb. 11 at 11:34 PM
$AQST Interesting close, looking forward to seeing the follow through upward in the morning 🤙🏼😎🍻
0 · Reply
Biotechnicity
Biotechnicity Feb. 11 at 9:34 PM
$AQST There are several motivations as to why Barber did not produce the CRL in whole. 1. To feed his financier, hedge fund buddies cheap shares as the CRL confirms that this is nothing more than a perfunctory delay. 2. Because he’s panicked by the implications of what that document suggests. 3. Because the CRL contains heretofore unseen issues. Not fatal. But neither confided. I favor explanations 1 and 3 as 2 is pure 💩 and would not happen! Holding BullBeariciously
1 · Reply
newmoneyking
newmoneyking Feb. 11 at 8:57 PM
$AQST got back into this day, second ride to 4s.
0 · Reply
Outrageous
Outrageous Feb. 11 at 8:48 PM
$AQST CEO Sees Clear Path Ahead After FDA Rejects Anaphylm Epi Film By: Jenifer Goodwin in Food Allergy, Food Allergy News Published: February 9, 2026 https://www.allergicliving.com/2026/02/09/ceo-sees-clear-path-ahead-after-fda-rejects-anaphylm-epi-film/
4 · Reply
Mylo24
Mylo24 Feb. 11 at 7:30 PM
$AQST Shorts have their asses hanging in the wind. SPRY hit 11+ between derisking CRL and approval.
1 · Reply
SP43
SP43 Feb. 11 at 6:50 PM
$AQST lots of red today
1 · Reply
ae1213
ae1213 Feb. 11 at 6:46 PM
$AQST could someone here recommend some good investment videos from YouTube or X? I know you guys follow them. I made me some good $ here and need solid investment ideas from videos. Only serious replies, please
1 · Reply
UnderLion16
UnderLion16 Feb. 11 at 5:53 PM
$AQST Your order to buy 1,100 shares of AQST through your individual (•••xxx) account has been filled at an average price of $3.67 per share. Your order is complete.
1 · Reply
BigGainTom
BigGainTom Feb. 11 at 5:15 PM
$AQST notice short idiots like @ae1213 and @stone52 is that they don't tell you to buy $SPRY. Spry is utter garbage. Poor sales and extreme losses. Wall Street shorts companies like Spry to bankruptcy.
2 · Reply
drose0527
drose0527 Feb. 11 at 5:02 PM
$AQST Good morning all you fellow Questive people. looking to add more cash covered puts in may or august looking to rebuy my 6500 shares in the 2's. as for the bears keep walking that price lower cause ill take everything i can get of this gem at a lower price. while capitalizing upon your stupidity for shorting this stock. good luck longs and stay the course. with pressure comes gems ruby's diamond's emerald's and AQST
1 · Reply
Latest News on AQST
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics

Feb 10, 2026, 10:14 AM EST - 1 day ago

SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics

INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics

Feb 7, 2026, 10:23 AM EST - 4 days ago

INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics

SHAREHOLDER INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics

Feb 5, 2026, 6:50 PM EST - 6 days ago

SHAREHOLDER INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics

AQST Investors Have Opportunity to Join Aquestive Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Feb 2, 2026, 1:24 PM EST - 9 days ago

AQST Investors Have Opportunity to Join Aquestive Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

What's Going On With Aquestive Therapeutics Stock After FDA Update For Lead Allergic Treatment?

Feb 2, 2026, 1:12 PM EST - 9 days ago

What's Going On With Aquestive Therapeutics Stock After FDA Update For Lead Allergic Treatment?

Aquestive Therapeutics, Inc. (AQST) Discusses FDA Complete Response Letter and Next Steps for Anaphylm Epinephrine Sublingual Film Transcript

Feb 2, 2026, 11:00 AM EST - 9 days ago

Aquestive Therapeutics, Inc. (AQST) Discusses FDA Complete Response Letter and Next Steps for Anaphylm Epinephrine Sublingual Film Transcript

US FDA declines to approve Aquestive's oral drug for allergic reactions

Feb 2, 2026, 7:10 AM EST - 9 days ago

US FDA declines to approve Aquestive's oral drug for allergic reactions

Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™

Feb 2, 2026, 7:00 AM EST - 9 days ago

Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™

AQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics

Feb 1, 2026, 9:03 PM EST - 10 days ago

AQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics

Aquestive Therapeutics Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through the Firm's Investigation

Jan 13, 2026, 10:59 AM EST - 4 weeks ago

Aquestive Therapeutics Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through the Firm's Investigation

Aquestive Therapeutics: Anaphylm Will Probably Survive This Regulatory Hurdle

Jan 12, 2026, 8:09 PM EST - 4 weeks ago

Aquestive Therapeutics: Anaphylm Will Probably Survive This Regulatory Hurdle

INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics

Jan 12, 2026, 5:03 PM EST - 4 weeks ago

INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics

Aquestive Stock Slides After FDA Flags Issues With Allergy Drug Application

Jan 9, 2026, 11:28 AM EST - 4 weeks ago

Aquestive Stock Slides After FDA Flags Issues With Allergy Drug Application

BREAKING: Aquestive Therapeutics Investigated for Securities Fraud After FDA Identifies Deficiencies; Investors Should Contact Block & Leviton To Potentially Recover Losses

Jan 9, 2026, 10:06 AM EST - 4 weeks ago

BREAKING: Aquestive Therapeutics Investigated for Securities Fraud After FDA Identifies Deficiencies; Investors Should Contact Block & Leviton To Potentially Recover Losses

Aquestive Therapeutics Announces Regulatory Development for Anaphylm™ (dibutepinephrine) Sublingual Film and Provides Business Update

Jan 9, 2026, 7:00 AM EST - 4 weeks ago

Aquestive Therapeutics Announces Regulatory Development for Anaphylm™ (dibutepinephrine) Sublingual Film and Provides Business Update

Aquestive Therapeutics: Looking For The PDUFA Run-Up

Jan 9, 2026, 4:21 AM EST - 4 weeks ago

Aquestive Therapeutics: Looking For The PDUFA Run-Up

Aquestive Therapeutics, Inc. (AQST) Discusses Anaphylm Regulatory Progress, Commercial Strategy, and Pipeline Development Transcript

Nov 7, 2025, 5:16 AM EST - 3 months ago

Aquestive Therapeutics, Inc. (AQST) Discusses Anaphylm Regulatory Progress, Commercial Strategy, and Pipeline Development Transcript

Aquestive Therapeutics, Inc. (AQST) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 12:36 PM EST - 3 months ago

Aquestive Therapeutics, Inc. (AQST) Q3 2025 Earnings Call Transcript

Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET

Oct 27, 2025, 7:00 AM EDT - 3 months ago

Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET

Aquestive Therapeutics: A Measured Bet

Oct 12, 2025, 2:57 AM EDT - 4 months ago

Aquestive Therapeutics: A Measured Bet

Aquestive Therapeutics Broadens Patent Estate for Anaphylm™

Oct 8, 2025, 7:00 AM EDT - 4 months ago

Aquestive Therapeutics Broadens Patent Estate for Anaphylm™

Aquestive Therapeutics: No AdCom For Anaphylm Derisks January Approval Catalyst

Sep 5, 2025, 12:40 PM EDT - 5 months ago

Aquestive Therapeutics: No AdCom For Anaphylm Derisks January Approval Catalyst

Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock

Aug 14, 2025, 6:28 AM EDT - 6 months ago

Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock

Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film

Aug 14, 2025, 6:00 AM EDT - 6 months ago

Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film

Aquestive Therapeutics, Inc. (AQST) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 10:19 AM EDT - 6 months ago

Aquestive Therapeutics, Inc. (AQST) Q2 2025 Earnings Call Transcript

Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 11, 2025, 4:01 PM EDT - 6 months ago

Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer

Jul 22, 2025, 7:00 AM EDT - 7 months ago

Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer

Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film

Jul 15, 2025, 7:00 AM EDT - 7 months ago

Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

Jul 7, 2025, 7:00 AM EDT - 7 months ago

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

Aquestive Therapeutics: Updating The Anaphylm Timeline To Approval

Jun 25, 2025, 8:03 AM EDT - 8 months ago

Aquestive Therapeutics: Updating The Anaphylm Timeline To Approval

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit

Jun 25, 2025, 7:00 AM EDT - 8 months ago

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit

Aquestive Therapeutics: Anaphylm Could Gain Significant Market Share

Jun 8, 2025, 11:00 PM EDT - 8 months ago

Aquestive Therapeutics: Anaphylm Could Gain Significant Market Share

Aquestive Therapeutics, Inc. (AQST) Q1 2025 Earnings Call Transcript

May 13, 2025, 11:35 AM EDT - 9 months ago

Aquestive Therapeutics, Inc. (AQST) Q1 2025 Earnings Call Transcript

Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 4:01 PM EDT - 9 months ago

Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Aquestive Therapeutics: Unprofitable For A Few More Years, But Significant Upside Potential

May 4, 2025, 4:32 PM EDT - 10 months ago

Aquestive Therapeutics: Unprofitable For A Few More Years, But Significant Upside Potential

Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET

May 1, 2025, 7:00 AM EDT - 10 months ago

Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET

Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium

Apr 9, 2025, 7:00 AM EDT - 11 months ago

Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium

Aquestive Therapeutics: Oral Anaphylaxis NDA Opportunity Spells Buy

Mar 25, 2025, 8:35 AM EDT - 11 months ago

Aquestive Therapeutics: Oral Anaphylaxis NDA Opportunity Spells Buy

drew64
drew64 Feb. 11 at 11:34 PM
$AQST Interesting close, looking forward to seeing the follow through upward in the morning 🤙🏼😎🍻
0 · Reply
Biotechnicity
Biotechnicity Feb. 11 at 9:34 PM
$AQST There are several motivations as to why Barber did not produce the CRL in whole. 1. To feed his financier, hedge fund buddies cheap shares as the CRL confirms that this is nothing more than a perfunctory delay. 2. Because he’s panicked by the implications of what that document suggests. 3. Because the CRL contains heretofore unseen issues. Not fatal. But neither confided. I favor explanations 1 and 3 as 2 is pure 💩 and would not happen! Holding BullBeariciously
1 · Reply
newmoneyking
newmoneyking Feb. 11 at 8:57 PM
$AQST got back into this day, second ride to 4s.
0 · Reply
Outrageous
Outrageous Feb. 11 at 8:48 PM
$AQST CEO Sees Clear Path Ahead After FDA Rejects Anaphylm Epi Film By: Jenifer Goodwin in Food Allergy, Food Allergy News Published: February 9, 2026 https://www.allergicliving.com/2026/02/09/ceo-sees-clear-path-ahead-after-fda-rejects-anaphylm-epi-film/
4 · Reply
Mylo24
Mylo24 Feb. 11 at 7:30 PM
$AQST Shorts have their asses hanging in the wind. SPRY hit 11+ between derisking CRL and approval.
1 · Reply
SP43
SP43 Feb. 11 at 6:50 PM
$AQST lots of red today
1 · Reply
ae1213
ae1213 Feb. 11 at 6:46 PM
$AQST could someone here recommend some good investment videos from YouTube or X? I know you guys follow them. I made me some good $ here and need solid investment ideas from videos. Only serious replies, please
1 · Reply
UnderLion16
UnderLion16 Feb. 11 at 5:53 PM
$AQST Your order to buy 1,100 shares of AQST through your individual (•••xxx) account has been filled at an average price of $3.67 per share. Your order is complete.
1 · Reply
BigGainTom
BigGainTom Feb. 11 at 5:15 PM
$AQST notice short idiots like @ae1213 and @stone52 is that they don't tell you to buy $SPRY. Spry is utter garbage. Poor sales and extreme losses. Wall Street shorts companies like Spry to bankruptcy.
2 · Reply
drose0527
drose0527 Feb. 11 at 5:02 PM
$AQST Good morning all you fellow Questive people. looking to add more cash covered puts in may or august looking to rebuy my 6500 shares in the 2's. as for the bears keep walking that price lower cause ill take everything i can get of this gem at a lower price. while capitalizing upon your stupidity for shorting this stock. good luck longs and stay the course. with pressure comes gems ruby's diamond's emerald's and AQST
1 · Reply
jolo11
jolo11 Feb. 11 at 4:38 PM
$AQST SPRY down over 6% today, short percentage at 35%. Ouch!
1 · Reply
Biotechnicity
Biotechnicity Feb. 11 at 4:30 PM
$AQST ro—bust package. He was telling us all along.
0 · Reply
RobertWillard876
RobertWillard876 Feb. 11 at 3:59 PM
$AQST Aquestive Therapeutics; biotech (oral film pharma); commercial-stage, royalty-based; pipeline diversification; partnership dependent.
1 · Reply
prototyper
prototyper Feb. 11 at 3:54 PM
$AQST nice dip. Adding
1 · Reply
pistha
pistha Feb. 11 at 3:46 PM
$AQST
0 · Reply
Stockpsad
Stockpsad Feb. 11 at 3:00 PM
$SPRY Still holding on here. Would love to have a conversation surrounding recent fall. Was under the impression that stock would boom after $AQST CRL which I had priced approval in models where we are now. I understand the launch has had friction, but is it hard to imagine they wouldn't get it correct this time around with an additional year of competition only from injectors. Is this manipulation, or am I missing something!
3 · Reply
ImmxBeliever
ImmxBeliever Feb. 11 at 2:55 PM
$AQST $IOVA “Aging”
1 · Reply
Fire_Truck
Fire_Truck Feb. 11 at 2:51 PM
$IMMX Something is seriously wrong with this person. Extreme child like behavior. He's blocked me but will unblock me to make a comment and block aging right after. Now he's making posts on other forums that i visit.$IOVA $AQST It really is comical. Sadly.
2 · Reply
n44
n44 Feb. 11 at 2:50 PM
$AQST DEAD MONEY ———————— There is no need to hold this stock For 10 months, Buy when they are 30 to 60 days from PDUFA
0 · Reply
111ggg
111ggg Feb. 11 at 2:49 PM
$AQST Not a good day in the bio world. Most dont report earnings until second week of March so not much action in any bio I own/watch.
0 · Reply
PukaBum
PukaBum Feb. 11 at 2:29 PM
$AQST Well this strengthens my theory that this Admin’s FDA is corrupt. Moderna’s highly effective (+27% more) mRNA flu vaccine application was blindsided and refused for BS reasons. Kinda sounds familiar… https://www.cnn.com/2026/02/10/health/fda-moderna-mrna-flu-vaccine
4 · Reply
ae1213
ae1213 Feb. 11 at 2:03 PM
$AQST Hello to my deflated shameless pumpers. I know that this company is worth $20 per share (I have learned it from Scam Sfera @DanSfera YouTube channel) and big pharma can’t wait to acquire it. It is just a matter of some price “consolidation” and then only up from there. Meanwhile as I promised you, sp has closed the gaps below $6, below $5, below $4. Now I have another challenge for you - let’s fill the $2.95 gap! I know we can do it together, it is just a matter of time. It would not happened by itself though. There are two upcoming catalysts which would make it possible. Guess what they are, you can do it, even the@stockman333699 with his reptilian brain can guess. See you at below $3 soon!
1 · Reply